Nothing said here yet.
to join the conversation.
| Juvenal Tobin WChief Commercial Officer | Sell | 5,341 | $195.6K | Wed, Oct 28 |
| Juvenal Tobin WChief Commercial Officer | Sell | 1,237 | $44.0K | Wed, Oct 28 |
| Juvenal Tobin WChief Commercial Officer | Sell | 3,288 | $108.8K | Mon, Oct 26 |
| MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 8,580 | $273.8K | Mon, Oct 19 |
| MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 3,198 | $102.0K | Mon, Oct 19 |
| MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 2,718 | $86.7K | Mon, Oct 19 |
| Juvenal Tobin WChief Commercial Officer | Sell | 3,288 | $110.6K | Mon, Oct 12 |
| MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 8,580 | $305.2K | Mon, Oct 5 |
| MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 3,198 | $113.7K | Mon, Oct 5 |
| MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 2,718 | $96.7K | Mon, Oct 5 |
| Oelschlager Kristen MChief Operating Officer | Sell | 2,807 | $100.3K | Thu, Oct 1 |
| Oelschlager Kristen MChief Operating Officer | Sell | 1,346 | $49.0K | Thu, Oct 1 |
In late September 2026, Castle Biosciences presented new data at the EADV Congress in Vienna showing that its DecisionDx-Melanoma i31-SLNB test identified patients with sentinel lymph node positivity below 5% and that eligible patients who avoided surgery had…
New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth FRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc.
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Shares of Castle Biosciences (CSTL) have recently risen about 37%, following increasing agreement among Wall Street analysts on earnings estimate revisions that point to a more constructive view of the company’s earnings outlook.
The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL).
Castle Biosciences, Inc.
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas.
Castle Biosciences (NASDAQ:CSTL) reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.
Moby summary of Castle Biosciences, Inc.'s Q2 2026 earnings call
Castle Biosciences raises 2026 revenue outlook to $365-$375M as TissueCypher volumes jump 63% and AdvanceAD-Tx secures favorable Medicare pricing.